



1. Mayo Clinic Laboratories utilizes the Meridian BreathID® qualitative spectrophotometry for analysis; with the Breath Test Kit, IDkit Hp™ Two. This system is indicated for use in adult patients and pediatric patients ages 3-17 years old. Safety and effectiveness has not been assessed in children below the age of 3 years.
2. Consider HELIS / *Helicobacter pylori* Culture with Antimicrobial Susceptibilities, *Varies*.
3. Antimicrobials, proton pump inhibitors, and bismuth preparations are known to suppress *H. pylori*. Ingesting these medications within 2 weeks prior to performing the breath test may produce false negative test results.
4. HPFRP / *Helicobacter pylori* with Clarithromycin Resistance Prediction, Molecular Detection, PCR, Feces has equivalent accuracy to fecal antigen testing for *H. pylori* detection and predicts clarithromycin susceptibility or resistance in *H. pylori* if detected. Although, fecal antigen testing is available elsewhere, Mayo Clinic providers prefer and recommend the use of molecular testing for the detection of *H. pylori*.
5. Consider HPFRP / *Helicobacter pylori* with Clarithromycin Resistance Prediction, Molecular Detection, PCR, Feces to assess for clarithromycin susceptibility if HELIS / *Helicobacter pylori* Culture with Antimicrobial Susceptibilities, *Varies* is not done.
6. Post treatment monitoring of *H. pylori* using the Meridian BreathID® should be performed after at least 6 weeks of treatment for *H. pylori* infection. Earlier assessment may give inaccurate results

